Thymogen
/ Synthetic dipeptide — L-glutamyl-L-tryptophanALIAS · Glu-Trp dipeptide · Thymic dipeptide (Khavinson) · EW dipeptide
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 3. Synthetic dipeptide identified in Khavinson-tradition Russian peptide bioregulator research; used clinically in Russia for immunostimulation in chronic infection and post-surgical recovery. Western primary-literature replication is limited.
Reported to enhance T-lymphocyte maturation and proliferation, with downstream effects on natural killer cell activity and cytokine balance. Specific receptor target not definitively identified; signalling claims rest primarily on lymphocyte function assays in cell culture and rodent immunodeficiency models.
Tier 3. Russian clinical literature includes small RCT-design studies in immunocompromised populations. No Phase 2 or 3 Western trials.
In published Russian clinical use, well tolerated. No comprehensive safety database meeting Western regulatory standards.
Regulatory status
- FDA status:
- Not FDA-approved
Khavinson-tradition peptide bioregulator literature carries the same methodological caveats as the broader Russian-origin small-peptide field — the work has not been independently replicated under contemporary Western trial methodology.